Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation.
The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs.
At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.
For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones.
The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising:
Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines.
The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up.
Implementation and evaluation take place at the same time. The evaluation includes:
At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-care pathway | No Intervention | This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. | |
| Care Pathway | Experimental | This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Implementation of a care pathway | Other | The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in self-management skills | There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress". | at the start of the therapy, after one and three months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in medication Adherence | after one and three months of therapy | |
| Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ) | after one and three months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS) | SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving. | at baseline (before the implementation of the care pathway) and after 24 months (during implementation) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lise-Marie Kinnaer, PharmD | Contact | 3216328265 | lisemarie.kinnaer@kuleuven.be | |
| Veerle Foulon, Prof. Dr. | Contact | veerle.foulon@kuleuven.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AZ Turnhout | Recruiting | Turnhout | Antwerpen | 2300 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31310353 | Derived | Kinnaer LM, Decoene E, Van Hecke A, Foulon V. Collaborative network to take responsibility for oral anticancer therapy (CONTACT): Study-protocol investigating the impact of a care pathway. J Adv Nurs. 2019 Dec;75(12):3726-3739. doi: 10.1111/jan.14157. Epub 2019 Aug 27. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D008175 | Lung Neoplasms |
| D008545 | Melanoma |
| D015179 | Colorectal Neoplasms |
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Change in patient satisfaction with care using Out-patsat 35 | The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations | at the start of the therapy, after one and three months |
| Health Related Quality of Life | at the start of the therapy, after one and three months |
| Change in Distress using the Distress Barometer | at the start of the therapy, after one and three months |
| Efficacy of treatment Using ECOG performance scale and RECIST criteria | at the start of the therapy, after one and three months |
| Toxicity of treatment | Summarizing adverse drug events | at the start of the therapy, after one and three months |
| Cost of care | Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …) | at the start of the therapy, after one and three months |
| Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure |
| at baseline (before the implementation of the care pathway) and after 24 months (during implementation) |
| Maria Middelares Gent | Recruiting | Ghent | Oost-Vlaanderen | 9000 | Belgium |
|
| Imelda Bonheiden | Recruiting | Bonheiden | Vlaams-Brabant | 2820 | Belgium |
|
| AZ Groeninge Kortrijk | Recruiting | Kortrijk | West-Vlaanderen | 8000 | Belgium |
|
| D017437 |
| Skin and Connective Tissue Diseases |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |